Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Technical advance

Evaluation of MetriGenix custom 4D™ arrays applied for detection of breast cancer subtypes

Aslaug Aamodt Muggerud1*, Hilde Johnsen1, Debra A Barnes2, Adam Steel2, Per Eystein Lønning4, Bjørn Naume3, Therese Sørlie1 and Anne-Lise Børresen-Dale1

Author Affiliations

1 Department of Genetics, Faculty division, The Norwegian Radium Hospital, University of Oslo, N-0310 Oslo, Norway

2 MetriGenix Corporation, Toronto, ON, Canada

3 Oncology, The Norwegian Radium Hospital, Oslo, Norway

4 Department of Oncology, Haukeland Hospital, University of Bergen, Norway

For all author emails, please log on.

BMC Cancer 2006, 6:59  doi:10.1186/1471-2407-6-59

Published: 15 March 2006

Abstract

Background

Previously, a total of five breast cancer subtypes have been identified based on variation in gene expression patterns. These expression profiles were also shown to be associated with different prognostic value. In this study tumour samples from 27 breast cancer patients, previously subtyped by expression analysis using DNA microarrays, and four controls from normal breast tissue were included. A new MetriGenix 4D™ array proposed for diagnostic use was evaluated.

Methods

We applied MetriGenix custom 4D™ arrays for the detection of previously defined molecular subtypes of breast cancer. MetriGenix 4D™ arrays have special features including probe immobilization in microchannels with chemiluminescence detection that enable shorter hybridization time.

Results

The MetriGenix 4D™ array platform was evaluated with respect to both the accuracy in classifying the samples as well as the performance of the system itself. In a cross validation analysis using "Nearest Shrunken Centroid classifier" and the PAM software, 77% of the samples were classified correctly according to earlier classification results.

Conclusion

The system shows potential for fast screening; however, improvements are needed.